Citius Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
Citius Pharmaceuticals, Inc., a Nevada corporation, filed this Current Report on Form 8-K on March 28, 2018, regarding a capital raise transaction closed on March 29, 2018. The company is engaged in pharmaceutical research and development.
Key Financial Metrics
- Gross Proceeds: Approximately $2.0 million from the sale of 669,504 shares of common stock and accompanying warrants.
- Net Proceeds: Approximately $1.7 million after deducting placement agent fees, expenses, and estimated offering costs.
- Share Price: $2.9850 per share.
- Warrant Terms: Warrants to purchase 669,504 shares issued at an exercise price of $2.86 per share, exercisable immediately for 5.5 years.
- Placement Agent Fees: 7% of gross proceeds plus warrants for 7% of shares sold, plus $35,000 in non-accountable expenses and $50,000 in legal/out-of-pocket expenses.
Material Changes
This filing represents a material change in the company's capital structure due to the issuance of new equity and warrants. The filing does not provide comparative financial data (revenue, profit, or cash flow) for prior periods as it is a transaction-specific report rather than a periodic financial statement.
Outlook, Management Commentary, and Risks
Use of Proceeds: Management intends to use net proceeds for general corporate purposes, specifically manufacturing expenses, clinical trial expenses, research and development, and general and administrative expenses.
Risks and Contingencies: The filing includes standard disclaimers that representations and warranties in the purchase agreements are for risk allocation between parties and should not be relied upon as factual statements of the company's condition. The warrants and shares issuable upon exercise were sold unregistered under Section 4(a)(2) and Rule 506 exemptions.
Investor Verification Checklist
- Verify the closing date of the transaction (March 29, 2018) and the actual receipt of net proceeds.
- Review the attached press release (Exhibit 99.1) for additional management commentary on the capital raise.
- Examine the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and ownership limitations.
- Confirm the dilution impact of the 669,504 new shares and the potential future dilution from the 669,504 investor warrants and placement agent warrants.
- Check subsequent filings for updates on the utilization of the $1.7 million in net proceeds.